The Impact of Hemoperfusion on Clinical Outcomes in Severe COVID-19 Patients: A Retrospective Propensity Score-Matched Study
Archives of Clinical Infectious Diseases · 30.04.2026 · 21 (2)
DOI: 10.5812/archcid-171705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Infectious Diseases, online erschienen am 30.04.2026. Verfasst von Meysam Safi Keykaleh und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Severe COVID-19 is frequently complicated by hyperinflammation and is associated with a high mortality rate.
Objectives
Adjunctive hemoperfusion (HP) aims to remove inflammatory mediators; however, its clinical benefits remain controversial.
Methods
This retrospective 1:1 propensity score-matched case-control study included 70 patients with severe COVID-19 who were admitted to the intensive care unit (ICU) at Dr. Gharazi Hospital, Malayer, Iran, from March 2020 to September 2022. Patients received adjunctive HP using Jafron cartridges plus standard care (n = 35) or standard care alone (n = 35).
Results
After matching, baseline characteristics were well balanced. Adjunctive hemoperfusion was associated with a significantly greater reduction in C-reactive protein (46% ± 14% vs. 18% ± 9%; P < 0.001), a greater improvement in peripheral oxygen saturation (SpO2; +7% ± 2% vs. +2% ± 1%; P = 0.01), a shorter ICU length of stay (11.2 ± 4.1 vs. 16.5 ± 5.8 days; P = 0.03), and a lower need for mechanical ventilation (40.0% vs. 62.9%; P = 0.04). Mortality in the intensive care unit was numerically lower in the HP group (20.0% vs. 34.3%; P = 0.08) but did not reach statistical significance. No procedure-related deaths occurred.
Conclusions
In this propensity-matched cohort, adjunctive hemoperfusion was associated with attenuated systemic inflammation, improved oxygenation, a reduced need for mechanical ventilation, and a shorter ICU stay. These findings should be interpreted cautiously given the retrospective design.
Zitieren
APA
Keykaleh, M. S., Malmir, K., -Tabar, E. M., Rahnama, A., & Tavakoli, M. R. (2026). The Impact of Hemoperfusion on Clinical Outcomes in Severe COVID-19 Patients: A Retrospective Propensity Score-Matched Study. Archives of Clinical Infectious Diseases, 21(2). https://doi.org/10.5812/archcid-171705
Vancouver
Keykaleh MS, Malmir K, -Tabar EM, Rahnama A, Tavakoli MR. The Impact of Hemoperfusion on Clinical Outcomes in Severe COVID-19 Patients: A Retrospective Propensity Score-Matched Study. Archives of Clinical Infectious Diseases. 2026;21(2). doi:10.5812/archcid-171705
BibTeX
@article{Keykaleh2026,
author = {Keykaleh, Meysam Safi and Malmir, Komeil and -Tabar, Ehsan Movahedi and Rahnama, Akbar and Tavakoli, Mohamad Reza},
title = {The Impact of Hemoperfusion on Clinical Outcomes in Severe COVID-19 Patients: A Retrospective Propensity Score-Matched Study},
journal = {Archives of Clinical Infectious Diseases},
year = {2026},
volume = {21},
number = {2},
doi = {10.5812/archcid-171705}
}
EUVIMED